Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis

BACKGROUND: Neoadjuvant imatinib for gastrointestinal stromal tumors (GIST) of the rectum can reduce, but may not eliminate, risk of surgical morbidity from permanent bowel diversion. We sought to evaluate the cost-effectiveness of alternative strategies in rectal GIST patients requiring abdominoper...

Descripción completa

Detalles Bibliográficos
Autores principales: Farid, Mohamad, Ong, Johnny, Chia, Claramae, Tan, Grace, Teo, Melissa, Quek, Richard, Teh, Jonathan, Matchar, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412662/
https://www.ncbi.nlm.nih.gov/pubmed/32782781
http://dx.doi.org/10.1186/s13569-020-00135-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412662/
https://www.ncbi.nlm.nih.gov/pubmed/32782781
http://dx.doi.org/10.1186/s13569-020-00135-7

Ejemplares similares